From the source
From the source
Isomorphic Labs announces partnerships with Eli Lilly and Novartis.
Isomorphic Labs announced strategic collaborations with Eli Lilly and Company and Novartis.
The partnerships are multi-target, focused on small molecules, and have a potential combined value of nearly $3 billion, excluding future royalties.
Isomorphic Labs will receive $45 million upfront from Eli Lilly and $37.5 million upfront from Novartis.
From the source
Isomorphic Labs announces strategic collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties that may result from future drug sales, and are testament to Isomorphic’s approach to drug design and the progress we are making.
isomorphiclabs.com
